Brief: Neumora Therapeutics Announces Initiation Of Phase 2 Study Of Navacaprant In Bipolar Depression
14/05/2024 12:01
May 14 (Reuters) - Neumora Therapeutics Inc NMRA.O :
* NEUMORA THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 STUDY
OF
NAVACAPRANT IN BIPOLAR DEPRESSION
* NEUMORA THERAPEUTICS INC: DATA FROM KOASTAL-1 ANTICIPATED
IN Q4
* NEUMORA: EXPECTS TO REPORT TOPLINE DATA FROM PHASE 2
NAVACAPRANT
STUDY IN SECOND HALF OF 2025
Source text for Eikon: ID:nGNX89C5yw
Further company coverage: NMRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neumora Therapeutics
See all newsNeumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Neumora Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Neumora Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex